We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat in Store for IQVIA Holdings (IQV) in Q4 Earnings?
Read MoreHide Full Article
IQVIA Holdings Inc. (IQV - Free Report) is scheduled to report fourth-quarter 2018 results on Feb 14, before the opening bell.
Strength across segments, operating performance and tax efficiencies are likely to boost IQVIA Holdings’ results.
Over the past year, shares of IQVIA Holdings have gained 29%, significantly outperforming the 7.8% rise of the industry it belongs to and 1.9% gain of the Zacks S&P 500 composite.
Let’s see how things are shaping up for the announcement.
Strength Across Segments to Drive the Top Line
The Zacks Consensus Estimate for fourth-quarter 2018 revenues is pegged at $2.62 billion, indicating year-over-year growth of 21.1%. The upside is likely to be driven by strength across the company’s Research & Development Solutions (R&DS) and Technology & Analytics Solutions (TAS) segments. In third-quarter 2018, total revenues of $2.59 billion increased 5.2% year over year.
Segment wise, TAS should benefit from strength across real-world and analytical services and incremental revenues from acquisitions. Strategic collaborations such as the agreement with Roche, Genomics England and a technology deal with Theramex should help the company strengthen its technological solutions. Launch of a Software as a Service (“SaaS”) eConsent tool for use in clinical trials and development of SaaS safety platform are the other major positives.
R&DS segment is expected to benefit from volume-related increases in clinical services and lab testing volumes. Substantial organic growth is likely to be witnessed in the segment.
The Zacks Consensus Estimate for earnings per share (EPS) in the to-be-reported quarter is pegged at $1.47, indicating year-over-year growth of 5%. Tax efficiencies and solid operational performance are likely to boost the company’s bottom line.
In third-quarter 2018, adjusted earnings per share of $1.42 increased 19.3% year over year.
Our Model Suggests a Beat
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided, especially if they have a negative Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
IQVIA Holdings has an Earnings ESP of +0.37% and a Zacks Rank #3, a combination that increases the odds of an earnings beat.
Here are a few stocks from the broader Zacks Business Services sector that investors may consider as our model shows that these have the right combination of elements to beat on earnings:
Conduent Incorporated (CNDT - Free Report) has an Earnings ESP of +0.95% and a Zacks Rank #3. The company is slated to release fourth-quarter 2018 results on Feb 20.
ICF International (ICFI - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #3. The company is scheduled to report fourth-quarter 2018 results on Feb 26.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Image: Bigstock
Is a Beat in Store for IQVIA Holdings (IQV) in Q4 Earnings?
IQVIA Holdings Inc. (IQV - Free Report) is scheduled to report fourth-quarter 2018 results on Feb 14, before the opening bell.
Strength across segments, operating performance and tax efficiencies are likely to boost IQVIA Holdings’ results.
Over the past year, shares of IQVIA Holdings have gained 29%, significantly outperforming the 7.8% rise of the industry it belongs to and 1.9% gain of the Zacks S&P 500 composite.
Let’s see how things are shaping up for the announcement.
Strength Across Segments to Drive the Top Line
The Zacks Consensus Estimate for fourth-quarter 2018 revenues is pegged at $2.62 billion, indicating year-over-year growth of 21.1%. The upside is likely to be driven by strength across the company’s Research & Development Solutions (R&DS) and Technology & Analytics Solutions (TAS) segments. In third-quarter 2018, total revenues of $2.59 billion increased 5.2% year over year.
Segment wise, TAS should benefit from strength across real-world and analytical services and incremental revenues from acquisitions. Strategic collaborations such as the agreement with Roche, Genomics England and a technology deal with Theramex should help the company strengthen its technological solutions. Launch of a Software as a Service (“SaaS”) eConsent tool for use in clinical trials and development of SaaS safety platform are the other major positives.
R&DS segment is expected to benefit from volume-related increases in clinical services and lab testing volumes. Substantial organic growth is likely to be witnessed in the segment.
IQVIA Holdings Inc. Revenue (TTM)
IQVIA Holdings Inc. Revenue (TTM) | IQVIA Holdings Inc. Quote
Bottom-Line Expectations
The Zacks Consensus Estimate for earnings per share (EPS) in the to-be-reported quarter is pegged at $1.47, indicating year-over-year growth of 5%. Tax efficiencies and solid operational performance are likely to boost the company’s bottom line.
In third-quarter 2018, adjusted earnings per share of $1.42 increased 19.3% year over year.
Our Model Suggests a Beat
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided, especially if they have a negative Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
IQVIA Holdings has an Earnings ESP of +0.37% and a Zacks Rank #3, a combination that increases the odds of an earnings beat.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. Price and EPS Surprise | IQVIA Holdings Inc. Quote
Other Stocks to Consider
Here are a few stocks from the broader Zacks Business Services sector that investors may consider as our model shows that these have the right combination of elements to beat on earnings:
Copart (CPRT - Free Report) has an Earnings ESP of +1.63% and a Zacks Rank #2. The company is expected to report second-quarter fiscal 2019 results on Feb 25. You can see the complete list of today’s Zacks #1 Rank stocks here.
Conduent Incorporated (CNDT - Free Report) has an Earnings ESP of +0.95% and a Zacks Rank #3. The company is slated to release fourth-quarter 2018 results on Feb 20.
ICF International (ICFI - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #3. The company is scheduled to report fourth-quarter 2018 results on Feb 26.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free – See the Stocks It Turned Up for Today >>